Canada markets close in 6 hours 9 minutes

ARCA biopharma, Inc. (ABIO)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
2.2999+0.0009 (+0.04%)
As of 09:35AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close2.2990
Open2.2500
Bid2.2600 x 800
Ask2.2900 x 800
Day's Range2.2500 - 2.2999
52 Week Range1.7100 - 3.9000
Volume3,339
Avg. Volume160,832
Market Cap33.142M
Beta (5Y Monthly)2.20
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review

    WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor. In April 2022, the Board of Directors established a Special Committee to explore and evaluate strategic options for maximizing stockholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or

  • GlobeNewswire

    ARCA biopharma Announces First Quarter 2022 Financial Results

    Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., May 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2022 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s Pres

  • GlobeNewswire

    ARCA biopharma Establishes Special Committee of the Board of Directors

    WESTMINSTER, Colo., April 18, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that its Board of Directors has established a Special Committee to evaluate strategic options for maximizing stockholder value. The Company believes there are multiple potential opportunities to enhance value for ARCA stockholders. The Special Committ